EUVIMEDEUVIMED entdecken
Crossref

Systemic anti-cancer treatment for Māori with stage III and IV non-small cell lung cancer in Aotearoa New Zealand

Kelson Tu'akoi, Janice Wong, Ha Nguyen, Chunhuan Lao, Mark Elwood, Mark McKeage, Ross Lawrenson

New Zealand Medical Journal · 2025

DOI: 10.26635/6965.6917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New Zealand Medical Journal, 2025. Verfasst von Kelson Tu'akoi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Respiratory Registrar, Waikato Hospital, Hamilton, Aotearoa New Zealand. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Gefördert von: Health Research Council of New Zealand..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

aims: We aimed to assess the frequency of systemic anti-cancer therapy (SACT) use in patients with advanced non-small cell lung cancer (NSCLC), comparing Māori and non-Māori. Secondary aims were to assess predictive factors for patients managed with SACT, SACT agent regimens and lung cancer–specific mortality. methods: A retrospective cohort study of patients with incident advanced NSCLC in the Aotearoa New Zealand Midland Region between 1 January 2011 to 31 December 2021 was undertaken. Data were primarily derived from the Midland Lung Cancer Registry. results: The study cohort comprised 2,549 patients with incident advanced NSCLC. A total of 775 patients were Māori (30%). SACT was received by 942 patients (37%). There was no difference in overall SACT rate between Māori and non-Māori: adjusted odds ratio (OR) 0.88 (95% confidence interval [CI] 0.71–1.09), p-value >0.05. For patients who received SACT, Māori were less likely to receive targeted therapy first-line (8.5% vs 16.1%, p-value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansNew ZealandFemaleMaleRetrospective StudiesAgedMiddle AgedNeoplasm StagingAged, 80 and overRegistriesMaori People

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Advanced Respiratory Registrar, Waikato Hospital, Hamilton, Aotearoa New Zealand.
  • Respiratory Physician, Waikato Hospital, Hamilton, Aotearoa New Zealand.
  • Research Fellow, Medical Research Centre, University of Waikato, Hamilton, Aotearoa New Zealand.
  • Senior Research Fellow, Medical Research Centre, University of Waikato, Hamilton, Aotearoa New Zealand.
  • Sub-Editor NZMJ; Honorary Professor of Cancer Epidemiology, Faculty of Medical and Health Sciences, The University of Auckland, Aotearoa New Zealand.
  • Medical Oncologist, Auckland City Hospital, Aotearoa New Zealand; Professor of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Aotearoa New Zealand.

Förderung

  • Health Research Council of New Zealand.

Zitieren

APA

Tu'akoi, K., Wong, J., Nguyen, H., Lao, C., Elwood, M., McKeage, M., & Lawrenson, R. (2025). Systemic anti-cancer treatment for Māori with stage III and IV non-small cell lung cancer in Aotearoa New Zealand. New Zealand Medical Journal. https://doi.org/10.26635/6965.6917

Vancouver

Tu'akoi K, Wong J, Nguyen H, Lao C, Elwood M, McKeage M, et al. Systemic anti-cancer treatment for Māori with stage III and IV non-small cell lung cancer in Aotearoa New Zealand. New Zealand Medical Journal. 2025. doi:10.26635/6965.6917

BibTeX
@article{Tuakoi2025,
  author = {Tu'akoi, Kelson and Wong, Janice and Nguyen, Ha and Lao, Chunhuan and Elwood, Mark and McKeage, Mark and Lawrenson, Ross},
  title = {Systemic anti-cancer treatment for Māori with stage III and IV non-small cell lung cancer in Aotearoa New Zealand},
  journal = {New Zealand Medical Journal},
  year = {2025},
  doi = {10.26635/6965.6917}
}
Kostenlos starten →